Protective effects of Fraxinus Micrantha against thioacetamide-induced hepatic encephalopathy: a focus on antioxidant and neuroprotective mechanisms.

IF 3.5 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Ritupal, Tanveer Singh, Hasandeep Singh, Balbir Singh
{"title":"Protective effects of Fraxinus Micrantha against thioacetamide-induced hepatic encephalopathy: a focus on antioxidant and neuroprotective mechanisms.","authors":"Ritupal, Tanveer Singh, Hasandeep Singh, Balbir Singh","doi":"10.1007/s11011-025-01713-8","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatic encephalopathy (HE) is a multifaceted neuropsychiatric syndrome frequently observed in patients with liver dysfunction. The present study aimed to evaluate the therapeutic effects of Fraxinus micrantha (F. micrantha) in thioacetamide (TAA)-induced HE model. HE was induced using TAA (200 mg/kg i.p.) for once every 48 h for 14 consecutive days in rats. Ethyl acetate fraction of F. micrantha (EAFM) (50, 100, and 200 mg/kg) was administered for 14 consecutive days (p.o.) after HE induction. TAA induced hepatotoxicity and HE, evidenced by significant alterations in liver biomarkers alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), lipid profiles (triglycerides, cholesterol), and neurotransmitter levels (serotonin, acetylcholine, dopamine, norepinephrine). Histopathological analysis revealed severe liver necrosis, inflammation, and brain damage, characterized by reduced neuronal density and hippocampal degeneration. EAFM treatment produced a significant, dose-dependent amelioration of TAA-induced liver injury, evidenced by the normalization of serum biomarkers (ALT, AST, ALP) and lipid profiles (cholesterol, triglycerides), with the 200 mg/kg dose showing efficacy comparable to silymarin. EAFM also exerted potent neuroprotective effects, restoring the altered levels of key neurotransmitters (serotonin, dopamine, norepinephrine) and reducing elevated acetylcholinesterase activity in the brain cortex and hippocampus. Furthermore, EAFM significantly mitigated oxidative stress by replenishing depleted reduced glutathione (GSH) levels in both hepatic and brain tissues. Histopathological analysis confirmed these findings, demonstrating that EAFM attenuated TAA-induced hepatocellular necrosis, inflammation, and hippocampal neurodegeneration. The results indicate that F. micrantha confers robust hepatoprotective and neuroprotective effects against HE, primarily mediated through its antioxidant activity and restoration of neurochemical balance, positioning it as a promising therapeutic candidate.</p>","PeriodicalId":18685,"journal":{"name":"Metabolic brain disease","volume":"40 7","pages":"278"},"PeriodicalIF":3.5000,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolic brain disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11011-025-01713-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatic encephalopathy (HE) is a multifaceted neuropsychiatric syndrome frequently observed in patients with liver dysfunction. The present study aimed to evaluate the therapeutic effects of Fraxinus micrantha (F. micrantha) in thioacetamide (TAA)-induced HE model. HE was induced using TAA (200 mg/kg i.p.) for once every 48 h for 14 consecutive days in rats. Ethyl acetate fraction of F. micrantha (EAFM) (50, 100, and 200 mg/kg) was administered for 14 consecutive days (p.o.) after HE induction. TAA induced hepatotoxicity and HE, evidenced by significant alterations in liver biomarkers alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), lipid profiles (triglycerides, cholesterol), and neurotransmitter levels (serotonin, acetylcholine, dopamine, norepinephrine). Histopathological analysis revealed severe liver necrosis, inflammation, and brain damage, characterized by reduced neuronal density and hippocampal degeneration. EAFM treatment produced a significant, dose-dependent amelioration of TAA-induced liver injury, evidenced by the normalization of serum biomarkers (ALT, AST, ALP) and lipid profiles (cholesterol, triglycerides), with the 200 mg/kg dose showing efficacy comparable to silymarin. EAFM also exerted potent neuroprotective effects, restoring the altered levels of key neurotransmitters (serotonin, dopamine, norepinephrine) and reducing elevated acetylcholinesterase activity in the brain cortex and hippocampus. Furthermore, EAFM significantly mitigated oxidative stress by replenishing depleted reduced glutathione (GSH) levels in both hepatic and brain tissues. Histopathological analysis confirmed these findings, demonstrating that EAFM attenuated TAA-induced hepatocellular necrosis, inflammation, and hippocampal neurodegeneration. The results indicate that F. micrantha confers robust hepatoprotective and neuroprotective effects against HE, primarily mediated through its antioxidant activity and restoration of neurochemical balance, positioning it as a promising therapeutic candidate.

薇甘菊对硫代乙酰胺诱导的肝性脑病的保护作用:对抗氧化和神经保护机制的研究
肝性脑病(HE)是一种多面性神经精神综合征,常见于肝功能障碍患者。本研究旨在评价微红花曲霉(Fraxinus microrantha)对硫乙酰胺(TAA)诱导的HE模型的治疗作用。采用TAA (200 mg/kg i.p)每48 h 1次诱导大鼠HE,连续14天。在HE诱导后连续14天(p.o)给药薇甘菊乙酸乙酯部位(EAFM)(50、100和200 mg/kg)。TAA诱导肝毒性和HE,肝脏生物标志物丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、碱性磷酸酶(ALP)、脂质谱(甘油三酯、胆固醇)和神经递质水平(血清素、乙酰胆碱、多巴胺、去甲肾上腺素)的显著改变证明了这一点。组织病理学分析显示严重的肝坏死、炎症和脑损伤,以神经元密度降低和海马变性为特征。EAFM治疗对taa诱导的肝损伤产生了显著的剂量依赖性改善,血清生物标志物(ALT、AST、ALP)和脂质谱(胆固醇、甘油三酯)的正常化证明了这一点,200 mg/kg剂量的疗效与水飞蓟素相当。EAFM还发挥了强大的神经保护作用,恢复了关键神经递质(血清素、多巴胺、去甲肾上腺素)的改变水平,降低了大脑皮层和海马中乙酰胆碱酯酶活性的升高。此外,EAFM通过补充肝脏和脑组织中耗尽的还原型谷胱甘肽(GSH)水平,显著减轻了氧化应激。组织病理学分析证实了这些发现,表明EAFM减轻了taa诱导的肝细胞坏死、炎症和海马神经变性。结果表明,薇甘菊对HE具有强大的肝保护和神经保护作用,主要通过其抗氧化活性和恢复神经化学平衡介导,使其成为一种有前景的治疗候选者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Metabolic brain disease
Metabolic brain disease 医学-内分泌学与代谢
CiteScore
5.90
自引率
5.60%
发文量
248
审稿时长
6-12 weeks
期刊介绍: Metabolic Brain Disease serves as a forum for the publication of outstanding basic and clinical papers on all metabolic brain disease, including both human and animal studies. The journal publishes papers on the fundamental pathogenesis of these disorders and on related experimental and clinical techniques and methodologies. Metabolic Brain Disease is directed to physicians, neuroscientists, internists, psychiatrists, neurologists, pathologists, and others involved in the research and treatment of a broad range of metabolic brain disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信